Obesity, NASH, RA deals among J&J's latest partnerships

The Johnson & Johnson Innovation unit of Johnson & Johnson (NYSE:JNJ) announced several partnerships, including collaborations concerning obesity, non-alcoholic steatohepatitis and rheumatoid arthritis.

J&J's Janssen Pharmaceuticals Inc. unit partnered with

Read the full 296 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE